Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brimapitide - Altamira Therapeutics/Xigen

Next Previous
X
Search
Drug Profile

Brimapitide - Altamira Therapeutics/Xigen

Alternative Names: AM-111; AM111 peptide; D-JNKI-1; Sonsuvi; XG-102; XG102 peptide

Latest Information Update: 06 Jun 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xigen
  • Developer Altamira Therapeutics; ribOvax Biotechnologies; Xigen
  • Class Anti-inflammatories; Antidementias; Cardiovascular therapies; Eye disorder therapies; Neuroprotectants; Peptides; Urologics
  • Mechanism of Action Mitogen-activated protein kinase 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sensorineural hearing loss
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hearing loss

Highest Development Phases

  • Phase III Ocular inflammation
  • Suspended Sensorineural hearing loss
  • No development reported Alzheimer's disease; Eye disorders; Interstitial cystitis; Kidney disorders; Stroke
  • Discontinued Ear disorders; Myocardial infarction; Parkinson's disease; Transplant rejection

Most Recent Events

  • 16 May 2023 Suspended - Phase-II for Sensorineural hearing loss in Poland (Intratympanic) prior to May 2023
  • 16 May 2023 Suspended - Phase-III for Sensorineural hearing loss in Canada, USA, South Korea, Asia, Czech Republic, Hungary, Spain, Bulgaria, Germany (Intratympanic) prior to May 2023
  • 16 May 2023 Suspended - Preclinical for Sensorineural hearing loss in Japan (Intratympanic) prior to May 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top